University of Debrecen Joins TriNetX Global Health Network

Health Information Networks

The University of Debrecen inked a partnership with TriNetX.  With $100 million in hand, TriNetX puts the capital to work expanding worldwide. TrialSite News noted TriNetX funds to fuel expansion worldwide. TriNetX has developed a disruptive model utilizing the concept of sharing electronic health record data by interfacing with site-focused electronic records. We have not seen an actual online demonstration but the system purports to support data-driven methodologies to clinical trial design, site selection and generation of real-world evidence (RWE).

The University of Debrecen serves more than half a million people in Hungary’s second largest city.  They provide state-of-the-art diagnostic and therapeutic procedures and engage in international clinical and academic research activities.  The university’s Denes Pall, Director of the Coordination Center for Drug Development for Debrecen was quoted by the TriNetX press release “Our immediate goal is to become experienced users and providers of data and harness the benefits of the TriNetX network.  We expect that both the number of and quality of studies we can participate in will increase now that we have made ourselves more visible to companies looking for experienced and cost-effective clinical sites.”

TriNetX claims now to span 23 countries and thousands of research sites—with data providers covering 99% of US health plans all representing a rapidly growing, data-driven research network representing 300 million patients.  How does this translate to opportunity? TriNetX touts that its network has been utilized to vet and analyze 16,000 protocols representing over 4,190 clinical trial opportunities.

Hungary’s University of Debrecen’s research focus includes cardiovascular, diabetes, oncology, pulmonology, gastroenterology, hematology, nephrology, dermatology and ophthalmology.

According to clinical trial outsource service provider Pharm-Olam Hungary represents an active participant in global clinical research. It offers the following strategic elements:

  • Gateway to Eastern European clinical trials (second most popular Eastern European country for clinical research next to Poland and Czech Republic)
  • Expedited Patient Recruitment (concentrated population utilizes central health system—this aligns with TriNetX strategy; strong physician/patient trust; Western-trained physicians
  • Motivated Investigator Network (additional research revenue incentive; Western research considered prestigious; large number of teaching hospitals)
  • Well-trained, skilled research staff (expedited timelines—typically within 60 days with CECs review included; many physicians and pharmacists with CRA and project management experience)

The U.S. National Institutes of Health (NIH) offers Hungary specific regulatory submission information. They note that although Hungary has harmonized its clinical trial legislation with the EU Clinical Trial Directive there are some differences between the country and the EU.  The NIH reports that at least back in 2015 the for most Hungarian trials the average start up time is 15 weeks; 6 weeks for approvals and 9 weeks to first site initiation.